Contents
Market Overview
The Netherlands holds a unique position in Europe’s cannabis landscape as the first country to establish a regulated medical cannabis framework, along with a state-supervised system for domestic cultivation and patient access. For many years, the Netherlands served as the primary global exporter of unlicensed medical cannabis, laying the groundwork for other European programmes that followed.
The estimated medical cannabis market size for 2025 is valued at over €3 million, with projections suggesting growth to €XXX million by 2029 (Prohibition Partners Market Sizing Forecasts, 2025–2029).
Despite its pioneering role, the Dutch medical cannabis market has remained relatively static in recent years. The country has not significantly scaled production or expanded patient access since its early 2000s inception. As a result, it now represents a modest domestic market compared to emerging European leaders such as Germany, the UK, and Denmark. Nevertheless, the Netherlands continues to rank among Europe’s top exporters of medical cannabis flower, maintaining its role as a central supplier to international markets.
Regulatory Framework
The Netherlands’ medical cannabis system operates under the Office of Medicinal Cannabis (OMC), which was established in 2001 under the Dutch Ministry of Health, Welfare and Sport (VWS). The OMC holds exclusive responsibility for licensing, supervision, and distribution of medical cannabis, ensuring compliance with both national law and the United Nations Single Convention on Narcotic Drugs (1961).
Key regulatory features include:
- Single authorised producer: Bedrocan Nederland B.V. operates under contract with the OMC as the sole licensed cultivator and manufacturer of medical cannabis.
- Government-controlled pricing: Bedrocan supplies all cannabis at a fixed price to the OMC, which manages domestic sales and international exports.
- Product forms: The OMC authorises several standardised dried flower and granulate products (e.g., Bedrocan, Bedrobinol, Bediol, Bedica, Bedrolite), available in defined THC/CBD ratios.
- Distribution: Products are dispensed through pharmacies via prescription, and exported under Good Manufacturing Practice (GMP) certification.
The system’s stability and traceability have made Dutch products highly regarded for pharmaceutical consistency, though critics argue that the lack of competition has limited innovation and patient choice.ed by the European Medicines Agency, such as Sativex, which remains available under a restricted prescription pathway.
Patient Access
Who Can Prescribe?
In the Netherlands, any registered physician may prescribe medical cannabis. Prescriptions may be issued for any condition where the physician deems there is reasonable evidence of therapeutic benefit. This open prescribing model distinguishes the Netherlands from more restrictive systems elsewhere in Europe.
Approved Indications (commonly prescribed):
While not limited by regulation, the most frequent medical uses include:
- Chronic neuropathic pain
- Multiple sclerosis-related spasticity
- Chemotherapy-induced nausea and vomiting
- Tourette’s syndrome
- Epilepsy
- Palliative symptom management
Reimbursement:
Reimbursement is not provided through the public healthcare system, but some private insurers may cover the cost on a case-by-case basis. Patients typically bear the full out-of-pocket cost, though pharmacy prices are relatively stable due to state-set wholesale rates.
Market and Industry Landscape
Bedrocan remains the exclusive domestic producer, supplying both the national market and international customers via OMC-authorised export agreements. The company maintains a consistent production output to meet contracted demand rather than expanding capacity.
The Netherlands exports to multiple European and international markets, including Germany, Italy, Finland, Poland, Australia, and Israel. These exports continue to account for the majority of Dutch production, highlighting the country’s ongoing export-oriented role within the global medical cannabis ecosystem.
While domestic demand has plateaued, the Netherlands’ expertise in standardised production, quality assurance, and compliance continues to underpin its influence across Europe’s regulatory and scientific frameworks.
Outlook
The Netherlands’ medical cannabis programme remains a benchmark of regulatory stability, prioritising pharmaceutical-grade quality and international compliance. However, limited product diversity, a monopolised supply chain, and lack of system innovation have constrained domestic market growth.
Unless the government liberalises its framework to allow new licence holders, expand product formats, or introduce structured reimbursement pathways, the Dutch market will remain modest in scale. Nonetheless, its role as an exporter and model for compliance ensures continued strategic importance within the broader European medical cannabis landscape.
